Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome

In March 2020, hydroxychloroquine (HCQ) and azithromycin were tested as potential treatments for COVID-19 pandemic, in an open label non-randomized clinical trial [1]. Data were collected from 36 confirmed COVID-19 patients after receiving no treatment (n = 16) or 200 mg q8h of HCQ with (n = 6) or without (n = 14) azithromycin depending on clinical status. Collected data over six days included one HCQ concentration per patient; respiratory viral loads (PCR assay); azithromycin co-treatment; and clinical status among other variables.

Using observed HCQ concentrations and basic pharmacokinetic equations, it was possible to calculate missing concentrations at all days for all patients (Supplementary Fig. S1). Daily viral load, presented as PCR threshold cycle (CT), was converted into a dichotomous variable (positive-PCR or negative-PCR). A logistic regression evaluated whether HCQ concentrations, azithromycin co-treatment (yes/no), clinical status (asymptomatic, upper or lower respiratory tract infection [URTI or LRTI]), time (day 0–6), and other covariates (age, sex) were associated with response (positive-PCR outcome).

Model evaluation and selection was performed based on statistical significance (p-value ≤ 0.05) and diagnostic plots (Supplementary Figs. S2, S3). The final model contained HCQ log-concentrations (ng/ml), azithromycin co-treatment, clinical status, and day as statistically significant covariates (Figs. 1 and S4).

Fig. 1
figure1

Predicted Probability of Positive-PCR across treatment days at average hydroxychloroquine concentration. *Points are observed data reported in Gautret et al. study. Solid lines and shaded areas are predicted probability with 95% confidence interval. ASYM asymptomatic, AZITH azithromycin co-treatment, HCQ hydroxychloroquine, URTI upper respiratory tract infection, LRTI lower respiratory tract infection; Legend: 0 means the respective drug is not taken while 1 means the respective drug is taken

Results showed that the odds of positive-PCR decrease by 53% for each unit increase in HCQ log-concentration. Similarly, the odds decrease by 61%, and by 12% for each day increase, and for azithromycin co-treatment, respectively. Whereas the odds of positive-PCR increase by 99.4 folds and 212 folds for having URTI and LRTI versus being asymptomatic subject.

Using the model, minimum HCQ concentrations to achieve > 50% probability of negative-PCR on day 3 were calculated, with or without azithromycin, for the clinical statuses. A minimum HCQ concentration (ng/ml) of 8103 (without azithromycin) and 282 (with azithromycin) are needed in subjects with LRTI. A minimum HCQ concentration (ng/ml) of 2441 (without azithromycin) and 83.9 (with azithromycin) are needed in subjects with URTI. Asymptomatic patients require minimal HCQ concentrations (< 2 ng/ml) regardless of azithromycin co-treatment.

Next, HCQ population PK model [2] was used to simulate dosing regimens needed to achieve targeted HCQ concentrations. Simulations showed that when HCQ is co-administered with azithromycin, a loading dose is critical in rapid achievement of targeted concentrations. The suggested dosing regimen for HCQ (with azithromycin), is 600 mg at 0 and 400 at 8 h followed by 200 mg q8h (Supplementary Fig. S5). When HCQ is administered without azithromycin, no safe and suitable HCQ dose can achieve targeted concentrations in LRTI and URTI patients (Supplementary Fig. S6).

The analysis confirms that co-treatment of COVID-19 with HCQ and azithromycin increases the probability of negative-PCR in patients. It also shows that clinical status affects the treatment outcome. This analysis is based on limited published data; therefore, the results should be interpreted with caution. The analysis cannot inform on the eventual patient outcome, it only evaluates time to undetectable viral load. Further clinical evaluation of HCQ and azithromycin are merited. Benefit-risk profile needs to be taken into account due to known adverse events associated with HCQ and azithromycin.

References

  1. 1.

    Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 20:20. https://doi.org/10.1016/j.ijantimicag.2020.105949:105949

    Article  Google Scholar 

  2. 2.

    Lim HS, Im JS, Cho JY, Bae KS, Klein TA, Yeom JS, Kim TS, Choi JS, Jang IJ, Park JW (2009) Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother 53(4):1468–1475

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Malek Okour.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Electronic supplementary material 1 (DOCX 15508 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Okour, M., Al-Kofahi, M. & Austin, D. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome. J Pharmacokinet Pharmacodyn 47, 187–188 (2020). https://doi.org/10.1007/s10928-020-09689-x

Download citation